Sapna Oberoi

Associate Professor

University of Manitoba
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (25)

Year:

2026

Purpose Infants with cancer are rare and face unique challenges. Our study aims to describe the incidence of infantile cancers in Canada and to compare treatment‐related mortality (TRM) and their outcomes with those of older children. Methods We conducted a retrospective cohort study using the Cancer in Young People in Canada database, including all infants (0 to <1 year old) with newly diagnosed cancer from 2001 to 2020. Population‐based data were used to estimate annual cancer incidence. Cox proportional hazards models were used to compare TRM, event‐free survival (EFS) and overall survival (OS) between (1) neonates (<30 days old) and older infants (≥30 days to <1 year old, (2) younger (<6 months) and older infants (≥ 6 months), and (3) all infants with older children (≥1 to ≤10 years old). Results A total of 2256 infants were included. The incidence was 30.8 per 100,000 infant‐years, and this incidence increased with an annual percent change of 1.6%, p < 0.001. Neonates had significantly higher TRM (6.1 vs. 3.6%, HR 2.76, p < 0.001) as well as infants younger than 6 months (5.2 vs. 2.7%, HR 2.05, p < 0.001). Compared with older children, infants experienced higher risk of TRM (4.1 vs. 2.1%, HR 2.45, p < 0.001) and had inferior 5‐year EFS (66.2 vs. 68.6%, HR 1.27, p < 0.001) and OS (77.5 vs. 78.6%, HR 1.22, p < 0.001). Conclusion The annual incidence of infantile cancers in Canada has increased and their outcomes are significantly worse than those of older children, as they face a higher risk of TRM, particularly in younger infants. Précis The incidence of cancer in infants has increased significantly in Canada between 2001 and 2020 and their outcomes are significantly lower than those of older children, being at greater risk of TRM.

Year:

2026

Year:

2026

Year:

2026

The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children’s Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI’s development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.

Year:

2026

Year:

2026

Year:

2026

Introduction CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi‐agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival. Methods This retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event‐free (EFS) and overall survival (OS) were estimated using Kaplan–Meier analysis; risk factors were assessed via log‐rank tests and Cox regression. Treatment response was assessed using RECIST. Results Among 27 patients (median age 21.5 years; range 8–83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died—3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow‐up of 18 months, 2‐year EFS was 56% vs. 8% ( p = 0.02) and OS was 67% vs. 23% ( p = 0.02) for localized vs. metastatic disease. Conclusion Complete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology‐driven therapies.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (26)

Sheila N. Garland

Professor

Memorial University

CANADA
View details

Douglas Hawkins

Professor

University of Washington

UNITED STATES
View details

Raya Saab

Stanford University

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Ajay Gupta

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Javed Khan

National Institutes of Health

UNITED STATES
View details

Omar F Khan

Clinical Assistant Professor, Medical Oncology

University of Calgary Cumming School of Medicine

CANADA
View details

Mohamed Abdelaal

Assistant Professor

University of Ottawa

CANADA
View details

Zoe Walters

Professor

University of Southampton

UNITED KINGDOM
View details

Rebecca Deyell

Clinical Associate Professor

The University of British Columbia

CANADA
View details

Mark Hatley

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Jessica L. Davis

Indiana University School of Medicine

UNITED STATES
View details

Catherine E. Cottrell

Nationwide Children's Hospital

UNITED STATES
View details

Janet Shipley

Group Leader, Sarcoma Molecular Pathology

Institute of Cancer Research

UNITED KINGDOM
View details

David Douglass

Associate Professor

University of Arkansas for Medical Sciences

UNITED STATES
View details

Susan M. Hiniker

Stanford University

UNITED STATES
View details

Sharon H.J. Hou

Assistant Professor

Simon Fraser University

CANADA
View details

Jack Brzezinski

Associate Professor

University of Washington

UNITED STATES
View details

Sara Israels

Professor

University of Manitoba

CANADA
View details

Jack Shern

Head, Tumor Evolution and Genomics Section

National Institutes of Health

UNITED STATES
View details

Joshua Rash

Professor

University of Saskatchewan

CANADA
View details

Marie-Claude Pelland-Marcotte

Assistant Professor under scholarship

Laval University

CANADA
View details

Gianni Bisogno

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Alyson Mahar

Queen's University

CANADA
View details

Kenneth Wong

-

UNITED STATES
View details

Lindsay Jibb

Assistant Professor

University of Toronto

CANADA
View details